London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Definitely
Perhaps the appointment of the joint broker has something to do with it?
Like a said a offer will come or on to Bigger things
Articles are all past tense and sound as if no offer is likely.
Market reaction tomorrow more likely down than up.
Thanks for pointing it out. Not a Daily Mail reader myself.
A PE enquiry at 10.50 to 11gbp.
Not sure that is a knockout bid...they need to offer a lot more premium....£14 would likely be enough.
Clin is not like cobham - that was on its knees as a result of bad contracts. Clin has a strong future to look forward to now that Iovance seems to be working for Proleukin.
Let’s see what the FY results bring
https://www.thisismoney.co.uk/money/news/article-8417997/Advent-International-bought-Cobham-eyes-Clinigen.html
Here is the article.
Times has it at 1.3bn
Whilst I think that a bid is unlikely it highlights the approximate value of £1.5bn that a buyer is willing to pay which will be around £11 per share.
I think it massively undervalues the company.
But it does show that the current SP is even more undervalued.
No one has picked up the speculation in the press today.
In the next 6 to 18 months there will be big changes for the better
either that or it's hit it's upper limit value wise, which i suspect is more likely, this dog hasn't been worth more than £9 ever, just ramped there
All red today as profit takers cash in
It’s been a very good share for me as I got shares when they first came out
I think Clinigen are going to go to higher things in the coming 12 months
Great little share this with good underpinning fundamentals.
Not holding many but enough to mature as this moves up steadily.
Clinigen Group PLC (LON:CLIN) shares climbed higher as investors and analysts saw positive read-across from trial data published overnight by Iovance Biotherapeutics Inc (NASDAQ:IOVA).
The US biotech reported interim data from 'cohort 4' of its pivotal phase-two study, where tests of its lifileucel treatment in melanoma met high expectations.
Lifileucel, a tumour infiltrating lymphocyte (TIL) therapy, delivered a 32% overall response rate, effectively matching the response shown in an earlier study.
Every full course of lifileucel requires about six doses of metastatic melanoma drug Proleukin, where Clinigen owns global rights.
Analysts at broker Liberum said the expectations for the pivotal P2 study were high and due to the implications for Clinigen's Proleukin, they have further upped their forecasts and share price target.
“This data looks considerably better than the current approved therapies and while there is still some more data to come, gives us confidence that the product will gain US approval in 2021.”
Certainly some momentum here, let's see what happens in coming weeks.
I bought more share yesterday morning
I can only see good things coming now J P Morgan are involved
AIM shares do not get the following and analysis they deserve and quite a few funds are not allowed to invest. There should be a maximum size and an automatic transfer to the main board, say £1bn. The additional regulations would benefit investors and broaden ownership generally positive uplift on the SP.
Been told it couldn’t be bench marked as big pensions companies will come in
But I rather it go on FTSE or the NASDAQ than be sold
I'm going to hold here too... big earnings increase coming in 6 weeks time. Even at £9 its undervalued
What are your thoughts as to target prices if moved on to FTSE?
I bought when they first floated and because my cousin owned it I tend to stay with them till they are either sold or put onto the FTSE
Liberum upgrade price to 1050 has helped today.
Hopefully Peel Hunt will be similarly emboldened.
These price surges on Aim are quite common so it will go higher and overshoot. I am going to hold...although if it does something silly like 1400 I will be tempted to sell and hope to buy back lower.
I see this share going up a fair bit over the next few months
Management certainly got their timing right.
I hope this rally persists....looking forward to more distribution deals and a strong FY performance. We may hear more at the FY trading update in July.
They work on shortages of drugs/ medicines all around the world
They know where to buy at good prices then distribute all around the world